Compare Revvity Inc (RVTY) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vale SA — how do they compare? Revvity Inc trades at $114.92 (market cap $12.91B), while Vale SA trades at $14.46 (market cap $61.97B). The key difference: Vale SA is far larger — about 4.8× Revvity Inc's market cap, and Vale SA pays the higher dividend (8.35%). Which is the better fit depends on your goals.
| RVTY | VALE | |
|---|---|---|
Market Cap | $12.91B | $61.97B |
Sector | Technology | Basic Materials |
52-Week High | $117.75 | $17.82 |
52-Week Low | $82.26 | $9.71 |
Enterprise Value | $15.23B | $78.22B |
Dividend Yield | 0.24% | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Vale S.A. (VALE) trades at $14.89, up 1.22% today, with a neutral technical stance. The company reported Q2 2026 EPS of $0.36, missing estimates of $0.41, continuing a trend of earnings misses. Revenue for 2025 was $38.40B, with net income margin at 5.11%. Cash flow from operations remains strong at $8.80B for 2025, supporting a $0.40 dividend scheduled for payment in September 2026.
The outlook is mixed: analyst consensus price target is $16.79 (12.8% upside), but rising costs and earnings misses pose risks. Base metals growth offers opportunity, yet iron ore volatility and debt increases require monitoring. The stock presents value with a P/E of 28.64 and EV/EBITDA of 7.65, but investor caution is warranted given recent performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
